Phase 3 N=20 Early Use of Vasopressin in Post-Fontan Management
Circulatory Perfusion Disorder · Congenital Heart Disease · Single-ventricle
Primary: Hemodynamics as Characterized by Vasoactive Inotrope Score (VIS) — 11; 11.3 units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=101 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Traumatic Shock
Primary: Number of Blood Products Transfused — 1.7; 3.0 Litre
Phase 3 N=153 Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:
Cardiac Disease
Primary: mPAP-to-MAP Ratio — 0.394; 0.385; 0.42; 0.40 ratio of mPAP-to-MAP — p=0.53
Phase 4 N=19 Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
Vasoplegic Syndrome · Liver Transplant; Complications
Primary: Systemic Vascular Resistance (SVR) — 480; 410; 588; 420 dyne*sec/cm^5
Phase 1 N=16 Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers
Renal Function Impairment in Healthy Volunteers
Primary: Renal Plasma Flow — 541; 663 mL/min — p=< 0.0001
N/A N=30 Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
Cerebral Vasospasm
Primary: Procedural Success — 64 Vessels Treated
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
N/A N=120 Optimal VAsopressor titraTION Pilot Randomized Controlled Trial
Hypotension · Shock
Primary: MAP While on Vasopressors — 79; 70 mmHg
N/A N=96 Effect of Epinephrine/ Phenylephrine for Preventing the Postreperfusion Syndrome During Reperfusion in Liver Transplantation
Hypotension After Reperfusion in Liver Transplantation
Primary: Occurrence of Postreperfusion Syndrome (PRS) — 45; 39; 87 percentage of participants
N/A N=16 Vasopressin in Intraabdominal Pressure Elevation
Intracranial Pressure Increase · Abdominal Compartment Syndrome
Primary: Changes in Vasopressin Levels During Pneumoperitoneum and Elevated PEEP — 2.37; 45.48; 54.75; 31.57 pg/ml — p=<0.0001
N/A N=70 Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants
Hypotension
Primary: Number of Subjects in Each Group Who Have Achieved an Optimal Mean Blood Pressure Value at 24 Hours of Life — 9; 9 participants
N/A N=133 Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock
Septic Shock
Primary: Total Vasopressor Dose — 13.7; 13.1; 13.2; 11.3 mg
Phase 4 N=89 Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
Acute Decompensated Heart Failure
Primary: Renal Function by Serum Creatinine — 1.3; 1.3; 1.3; 1.4 mg/dL
Phase 3 N=50 Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Phase 2 N=12 Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
N/A N=96 Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Traumatic Brain Injury
Primary: Time ICP >20 — 1.7; .9 Hours
Phase 3 N=136 Midodrine for the Treatment of Refractory Hypotension
Hypotension · Critical Illness
Primary: Time Until Discontinuation of IV Vasopressors — 23.5; 22.5 hours
N/A N=80 Nitroglycerin Infusion During Cardiac Surgery
Lactic Acidosis · Blood Glucose, High
Primary: Plasma Lactate Level, Before Incision — 1.1; 1.0 mmol/L — p=0.618
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
Phase 3 N=501 Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
Heart Arrest
Primary: Number of Participants With Return of Spontaneous Circulation — 100; 86 participants
Phase 2 N=44 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Heart Failure · Congestive Heart Failure
Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio
Phase 3 N=12 Use of Vasopressin Following the Fontan Operation
Pleural Effusion · Single-ventricle
Primary: Chest Tube Drainage — 686.83; 535.50 ml/kg
Phase 4 N=20 Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
Shock, Surgical · Shock · Hypotension and Shock
Primary: Duration of ATII Vasopressor Usage in the Intraoperative Setting — 1 hours
Phase 2 N=65 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Primary: Raynaud's Symptom Severity (Change From Baseline) — -20.19; -18.63 score on a scale
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
Phase 4 N=3,626 Norepinephrine vs Phenylephrine During General Anesthesia
Anesthesia · Surgery · Hypotension
Primary: Number of Participants With Assigned Vasopressor Given — 1570; 1627 Participants
Phase 4 N=28 Renin and Renal Biomarker Response to Angiotensin II
Septic Shock · Acute Kidney Injury
Primary: Change in Plasma Renin Levels — -15; 69; -6; 26 pg/mL
N/A N=420 RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)
Surgical Wound
Primary: Time to Hemostasis (TTH) — 21.4; 4.8 minutes
Phase 2 N=32 Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury
Traumatic Brain Injury
Primary: Safety and Tolerability of VAS203 in Patients With Moderate and Severe TBI — 8; 8; 6; 8 participants
Phase 3 N=203 Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
Critical COVID-19 With Respiratory Failure · Acute Respiratory Distress Syndrome (ARDS) · Corona Virus Infection
Primary: Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) — 72; 33 Participants